ArticleJournal of the American Society of Nephrology : JASN2026
Comparative Effectiveness of Different Influenza Vaccine Formulations among Patients Undergoing Maintenance Hemodialysis.
Article in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Influenza Vaccination in Dialysis: New Technologies for a Vulnerable Population.Journal of the American Society of Nephrology : JASN · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
key pointsIn patients with kidney failure, enhanced influenza vaccine formulations may provide modestly increased protection versus standard-dose vaccines. This cohort study compared the risk of influenza-like illness, influenza, influenza-related hospitalization, severe influenza, and all-cause mortality by vaccine formulation. Findings support new Centers for Disease Control and Prevention guidelines recommending enhanced influenza vaccine formulations in adults ≥65 years, regardless of kidney failure.
backgroundInfluenza vaccination is recommended to prevent influenza in patients with kidney failure. It remains unclear whether newer, enhanced vaccine formulations are more effective than standard-dose, egg-based, inactivated influenza vaccine (standard-dose vaccine) in patients undergoing maintenance hemodialysis. We sought to compare the effectiveness of five influenza vaccine formulations among patients undergoing hemodialysis.
methodsUsing the United States Renal Data System database, we performed an active comparator cohort study among adults ≥65 years with kidney failure undergoing hemodialysis (2011/2012-2019/2020 influenza seasons) who received a standard-dose, high-dose, cell culture-based, adjuvanted, or recombinant influenza vaccine within a given season. We compared the risk of influenza-like illness, influenza, influenza-related hospitalization, severe influenza, and all-cause mortality during the influenza season by vaccine formulation. Season-specific risk differences and relative vaccine effectiveness (rVE) were estimated using propensity score-weighted Kaplan-Meier functions, accounting for the competing risk of death (for nonmortality outcomes). We combined the season-specific estimates via a random effects meta-analysis.
results578,232 influenza patient-seasons included standard-dose vaccine ( n =372,907), high-dose vaccine ( n =192,880), cell culture-based vaccine ( n =8177), adjuvanted vaccine ( n =3308), or recombinant vaccine ( n =960). Season-specific and meta-analytic estimates were consistent with a modest protective effect of high-dose vaccine versus standard-dose vaccine for influenza (meta-analytic rVE 5.1%; 95% confidence interval [CI], -0.7% to 10.5%), influenza-related hospitalization (meta-analytic rVE 5.5%; CI, -1.8% to 12.3%), and severe influenza (meta-analytic rVE 13.7%; CI, -9.7% to 32.1%), but not influenza-like illness or mortality. Patterns were similar for cell culture-based vaccine versus standard-dose vaccine ( e.g ., meta-analytic rVE for influenza, 18.3%; CI, 2.2% to 31.7%). Estimates for adjuvanted or recombinant versus standard-dose vaccines were imprecise. Quantitative bias analyses did not indicate residual confounding, although some estimates were imprecise.
conclusionsAmong older adults undergoing hemodialysis, high-dose vaccine and cell culture-based vaccine provided modestly increased protection versus standard-dose vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.